Stadler WM - Search Results

1

Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma.

Atkins MB, Rini BI, Motzer RJ, Powles T, McDermott DF, Suarez C, Bracarda S, Stadler WM, Donskov F, Gurney H, Oudard S, Uemura M, Lam ET, Grüllich C, Quach C, Carroll S, Ding B, Zhu QC, Piault-Louis E, Schiff C, Escudier B. Atkins MB, et al. Among authors: stadler wm. Clin Cancer Res. 2020 Jun 1;26(11):2506-2514. doi: 10.1158/1078-0432.CCR-19-2838. Epub 2020 Mar 3. Clin Cancer Res. 2020. PMID: 32127394 Free PMC article. Clinical Trial.

2

Continuous-infusion fluorodeoxyuridine with leucovorin and high-dose interferon: a phase II study in metastatic renal-cell cancer.

Stadler WM, Vogelzang NJ, Vokes EE, Charette J, Whitman G. Stadler WM, et al. Cancer Chemother Pharmacol. 1992;31(3):213-6. doi: 10.1007/BF00685550. Cancer Chemother Pharmacol. 1992. PMID: 1464158 Clinical Trial.

3

High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: the University of Chicago experience.

Shulman KL, Stadler WM, Vogelzang NJ. Shulman KL, et al. Among authors: stadler wm. Urology. 1996 Feb;47(2):194-7. doi: 10.1016/S0090-4295(99)80414-2. Urology. 1996. PMID: 8607232

4

A phase II study of subcutaneous recombinant human interleukin-4 in metastatic renal cell carcinoma.

Stadler WM, Rybak ME, Vogelzang NJ. Stadler WM, et al. Cancer. 1995 Nov 1;76(9):1629-33. doi: 10.1002/1097-0142(19951101)76:9<1629::aid-cncr2820760920>3.0.co;2-q. Cancer. 1995. PMID: 8635068 Clinical Trial.

5

Metastatic bladder cancer: advances in treatment.

Stadler WM, Kuzel TM, Raghavan D, Levine E, Vogelzang NJ, Roth B, Dorr FA. Stadler WM, et al. Eur J Cancer. 1997 Jan;33 Suppl 1:S23-6. doi: 10.1016/s0959-8049(96)00337-1. Eur J Cancer. 1997. PMID: 9166096 Review.

6

Granulocyte-macrophage--colony stimulating factor in metastatic renal cell carcinoma: a phase II trial.

Rini BI, Stadler WM, Spielberger RT, Ratain MJ, Vogelzang NJ. Rini BI, et al. Among authors: stadler wm. Cancer. 1998 Apr 1;82(7):1352-8. doi: 10.1002/(sici)1097-0142(19980401)82:7<1352::aid-cncr19>3.0.co;2-5. Cancer. 1998. PMID: 9529028 Clinical Trial.

7

Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer.

Vogelzang NJ, Mani S, Schilsky RL, Ansari RH, Taber D, Rhinehart SN, Garcia JC, Meyer SC, Mick R, Brockstein BE, Stadler WM, Ratain MJ, Vokes EE. Vogelzang NJ, et al. Among authors: stadler wm. Clin Cancer Res. 1998 Apr;4(4):929-34. Clin Cancer Res. 1998. PMID: 9563886 Clinical Trial.

8

Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma.

Stadler WM, Kuzel T, Dumas M, Vogelzang NJ. Stadler WM, et al. J Clin Oncol. 1998 May;16(5):1820-5. doi: 10.1200/JCO.1998.16.5.1820. J Clin Oncol. 1998. PMID: 9586896 Clinical Trial.

9

Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials.

Ryan CW, Vogelzang NJ, Dumas MC, Kuzel T, Stadler WM. Ryan CW, et al. Among authors: stadler wm. Cancer. 2000 Mar 15;88(6):1317-24. Cancer. 2000. PMID: 10717612 Clinical Trial.

10

Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer.

Kaufman D, Raghavan D, Carducci M, Levine EG, Murphy B, Aisner J, Kuzel T, Nicol S, Oh W, Stadler W. Kaufman D, et al. J Clin Oncol. 2000 May;18(9):1921-7. doi: 10.1200/JCO.2000.18.9.1921. J Clin Oncol. 2000. PMID: 10784633 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

343 results

Search Page

Filters